| Valuation method | Value, £ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 38.00 | 3189 |
| Intrinsic value (DCF) | 1.65 | 43 |
| Graham-Dodd Method | n/a | |
| Graham Formula | n/a |
SHL Telemedicine Ltd. (LSE: 0QMX) is a pioneering Israeli telemedicine company specializing in personal remote cardiac and health monitoring solutions. Founded in 1987 and headquartered in Tel Aviv, SHL develops and markets innovative telemedicine devices such as SmartHeart (a mobile 12-lead ECG system), CardioSen'C, and remote monitoring tools for weight, blood pressure, lung function, and oxygen saturation. The company serves patients, healthcare providers, insurers, and hospitals globally, with a strong presence in Israel and Europe. SHL collaborates with leading institutions like Mayo Clinic and Hadassah Medical Center to enhance cardiac care through AI-driven ECG analysis. Operating in the rapidly growing $80B+ telemedicine market, SHL combines medical device expertise with digital health connectivity, positioning itself at the intersection of cardiology and remote patient monitoring technologies.
SHL Telemedicine presents a high-risk, high-reward proposition in the expanding telemedicine sector. While the company reported a CHF 7.1M net loss in 2023 on CHF 57.1M revenue, its specialized cardiac monitoring IP and collaborations with prestigious medical institutions offer growth potential. The low beta (0.24) suggests limited correlation to broader markets, but investors should note the negative operating cash flow (-CHF 1.5M) and significant debt (CHF 19.9M vs. CHF 6.7M cash). The lack of dividends reflects reinvestment needs. Key value drivers include adoption of its FDA-cleared SmartHeart technology and expansion of AI-powered diagnostics, though competition from larger medtech firms poses challenges. The sub-$50M market cap indicates this remains a speculative small-cap play.
SHL Telemedicine occupies a niche position in cardiac-focused remote monitoring, differentiating through its proprietary 12-lead ECG technology (uncommon in consumer devices) and hospital-grade data transmission. Its collaboration with Mayo Clinic provides clinical validation, while the AI development partnership with Hadassah Medical Center could yield predictive analytics advantages. However, the company faces scale disadvantages versus broader telemedicine platforms like Teladoc and medtech giants with deeper R&D budgets. SHL's focus on hardware+services bundling creates recurring revenue but requires significant capex (CHF 1.3M in 2023). Geographic concentration in Israel and Europe limits exposure to the larger U.S. market where reimbursement systems favor telehealth. The competitive moat lies in its cardiac specialization and FDA/CE clearances, though adoption depends on convincing healthcare systems to integrate its devices into care pathways. With gross margins pressured by device costs, SHL must achieve higher volume to offset its fixed telemedicine infrastructure expenses.